Summary We have detected somatostatin receptors (SSR) by autoradiography in 3/4 established small cell lung cancer (SCLC) cell lines but not in two non-SCLC cell lines. The growth of 1/3 SSR positive SCLC cell lines was significantly inhibited by the long-acting somatostatin analogue octreotide statin) 10-9M. We treated 20 SCLC patients with octreotide 250 gg three times daily for I week prechemotherapy (six patients) or at relapse after chemotherapy (14). Octreotide was well tolerated, and serum insulin-like growth factor-I levels were suppressed to 62±7% of pre-treatment levels. However there was no evidence of anti-tumour activity measured by tumour bulk or serum levels of neuron-specific enolase. In one patient metastatic skin nodules were shown to be SSR positive before and at the end of 2 weeks octreotide. Despite this the patient had progressive disease, and tumour cells obtained by fine needle aspirate before and after treatment showed no growth inhibition when cultured with octreotide immediately or following establishment as a cell line. In summary we saw little correlation between SSR expression and growth inhibition by octreotide, either in vitro or clinically.
Somatostatins are a family of 14-and 28-residue neuropeptides which regulate peptide secretion from the pituitary, gut and pancreas (Bloom & Polak, 1987; Frohman & Krieger, 1987) . Somatostatin receptors (SSR) are expressed by these so-called 'SS target tissues', and by tumours arising from them including pituitary adenomas and pancreatic insulinomas (Reubi et al., 1982; 1984) . Natural SS-14 is of limited therapeutic use here because of its short plasma half-life (3 min) and diverse action (Moreau & DeFeudis, 1987; Schally, 1988) . Systematic structure/activity studies have led to the development of potent octapeptide SS analogues with prolonged and selective activity. One of these, octreotide Sandostatin) has pharmacological effects in vivo for up to 9 h and is 45-70 times more potent than SS-14 at inhibiting growth hormone release (Plewe et al., 1987; Schally, 1988) . In patients with acromegaly, carcinoid syndrome, insulinomas and other gastroenteropancreatic tumours, octreotide produces clinical improvement in parallel with suppression of inappropriate peptide secretion, and in some cases reduction in tumour bulk Wood et al., 1985; Kvols et al., 1986; Lamberts et al., 1987; Comi, 1989; Maton, 1989) . Octreotide and other octapeptide SS analogues have also shown experimental evidence of antiproliferative activity in some common solid tumours, including cancers of the breast, exocrine pancreas, colon and prostate (Setyono-Han et al., 1987; Schally, 1988; Parmar et al., 1989; Weber et al., 1989) . Growth inhibition here could be mediated directly, via SSR which have been detected on breast, pancreas and prostate cancers (Reubi et al., 1987; Setyono-Han et al., 1987; Srkalovic et al., 1990) , or indirectly via suppression of local or circulating levels of growth factors (Schally, 1988) .
There is some evidence that SS may play a role in growth regulation of small cell lung cancer (SCLC) . SS-like immunoreactivity has been detected in SCLC cells (Sorensen et al., 1981) . SSR are expressed in SCLC tumours and cultured cells but not by non-SCLC (Taylor et al., 1988a; Reubi et al., 1990) . The octapeptide SS analogue somatuline (BIM-23014C) has been shown to inhibit the growth of SCLC xenografts in immune-deprived mice (Taylor et al., 1988b; Bogden et al., 1990) .
We have assessed the in vitro response of SCLC and non-SCLC cells to octreotide, correlating SSR expression with effects on growth and secretion of insulin-like growth factor-I (IGF-I), an autocrine growth factor for lung cancer cells (Minuto et al., 1988; Macaulay et al., 1988a; . Results from these in vitro studies described below encouraged us to proceed to a clinical study, based on the fact that octreotide is a safe and well-tolerated drug (Parmar et al., 1989; Reubi et al., 1990) . The main part of this study involved patients who had relapsed off-treatment after initial response to conventional chemotherapy. In addition we tried to assess octreotide in previously untreated patients, over a 7 day period during admission for staging investigations prior to conventional chemotherapy. In this latter group we hoped that serum neuron-specific enolase, a tumour marker for SCLC (Carney et al., 1982) , would be sufficiently sensitive to permit evaluation of response especially in the group treated for 7 days before chemotherapy. We also measured circulating levels of IGF-I. We have shown that serum IGF-I levels do not correlate with tumour bulk in patients with SCLC (Macaulay et al., 1988b) and we used this parameter not as a tumour marker but rather as a measure of the endocrine effects of octreotide, as reported in acromegaly (Lamberts et al., 1988 (Carney et al., 1985; Duchesne et al., 1987; Macaulay et al., 1987) (Miller et al., 1981) and by serial serum levels of NSE and IGF-I. Side effects were graded as mild (grade 1), moderate (2), or severe (3).
Growth assays
Octreotide was provided by Dr P. Marbach, Sandoz, Basle. It was dissolved in sodium acetate buffer pH 6 with 0.1% bovine serum albumin (SMS buffer). 3H thymidine incorporation assays were performed in sterile 96-well microtitre plates (Macaulay et al., 1988a) . Single cell suspensions were preparing by syringing (SCLC) or trypsinisation (non-SCLC). Assays used cultured cells (6 x 103/well) or fresh nucleated cells (105/well) obtained by fine needle aspirate of metastatic skin nodules. The cells were cultured in unsupplemented RMPI in the presence of octreotide 10-11-10-6M. Control wells received SMS buffer without octreotide. After 46 h incubation (37°C, 5% C02) the cells were labelled with 3H thymidine (Amersham) 0.4 gCi well, and after 24 h they were harvested and counted as previously described (Macaulay et al., 1988a (Zar, 1984 (Reubi et al., 1990) .
Radioimmunoassays for NSE and IGF-I Serum NSE was measured on duplicate samples by radioimmunoassay (Pharmacia Ltd, Milton Keynes, UK). For IGF-I assay, unconditioned and conditioned media were centrifuged (1,000 r.p.m., 5 min), lyophilised, and reconstituted in distilled water at one tenth the original volume. Samples of medium and patients' serum underwent acid ethanol extraction with 2 N hydrochloric acid: absolute ethanol, 1:7 and were neutralised with Tris buffer. Duplicate aliquots were assayed using anti-IGF-I monoclonal antibody BPL-M23 as previously described (Teale & Marks, 1986; . Analysis of variance and Dunnett's test were used to assess the significance of differences in NSE and IGF-I levels before and during octreotide therapy.
Results
Established lung cancer cell lines 3H thymidine incorporation assays were performed on HX149 and HCl2, to select octreotide doses for further study. Octreotide caused significant inhibition of 3H thymidine incorporation at I0-M in HX149 (63 ± 1% control, P<0.05; see Figure 1 ) and at 10-6 M in HC12 (87 ± 2%, P<0.05). We then tested the effect of octreotide 10-' and 10-6 M on growth and IGF-I secretion by lung cancer cells in longer term culture. In HX149 growing in RPMI plus 5% FCS, cell numbers were lower in octreotide-treated cultures (Figure 2 ). Inhibition was greatest in the presence of octreotide 10-9 M, but the effects of both 10-' and 10-6 M were significantly lower than control on days 9-16 (P<0.01). As we previously reported, HX149 secretes low levels of IGF-I, around 0.5 ng ml-'. It was not possible to discern any octreotide-induced alteration in IGF-I secretion in the presence of 5% FCS, which provides around 2-5 ng ml-I IGF-I (Macaulay et al., 1988a; . We attempted to circumvent this problem by performing experiments in unsupplemented RPMI or RPMI plus TIS, but HX149 did not grow satisfactorily without serum. Octreotide 10-' or 10-6 M had no effect on growth or IGF-I secretion by HC12, NCI-H69, ICR-SC17, NCI-H23 or NCI-H226. Table  I ). One patient with multiple metastatic skin nodules con- sented to further studies on the effect of octreotide on tumour cell growth and SSR expression (see below).
Serum was obtained for NSE and IGF-I assay in all patients before starting octreotide and serial samples were available in 18. Five of six previously untreated patients had high baseline NSE levels (>12ngml-') and of four with serial measurements one remained high, two fell slightly (39.5 to 29.5 and 14 to I0ngml['; P<0.05 in each case) and one rose significantly from 72 (pre-octreotide) to 200 (on treatment; P<0.05) to 78 (end of treatment). An early 'surge' in NSE has been previously noted in response to chemotherapy, where it may represent rapid destruction of NSE-producing cells (Nou et al., 1990 ). Thirteen of 14 relapsed patients had high pretreatment serum NSE levels. Of 12 with serial measurements, NSE levels fell from 28 to 9 ngml1l in one case (P<0.01). In six patients there was no statistically Four of six previously untreated patients completed the planned 7 days of octreotide therapy. Treatment was discontinued early in two cases, one for toxicity and the other for PD. All six patients went on to receive combination chemotherapy in a randomised trial comparing ACE with MVC. Five of the six responded to first-line chemotherapy, and all responded to first or second-line chemotherapy. This group had a median survival of 36 weeks (range 20-51) from the start of treatment. Octreotide was discontinued in one relapsed patients because of toxicity (local pain), and in the remaining 13 because of PD. From the start of octreotide therapy this group had a median survival of only 13 weeks (3-50).
Experimental studies in one patient with relapsed SCLC A patient with SCLC (LD), inappropriate antidiuretic hormone secretion, Lambert-Eaton myasthenic syndrome and autonomic neuropathy who had relapsed after ACE chemotherapy with metastatic skin/subcutaneous nodules, consented to nodule biopsy and aspiration before and 2 weeks after starting octreotide. During this period his tumour progressed. Changes in serum NSE and IGF-I are shown in Figure 3 . (Figure 4) . Fresh tumour cells obtained by fine needle aspiration again showed no inhibition of 3H thymidine incorporation in the presence of octreotide 10-10-6 M. This sample did not establish as a cell line.
Discussion
In this study SSR were expressed by 3/4 established SCLC cell lines but only 1/4 showed growth inhibition in response to octreotide. This effect occurred in HX149 which expresses SSR, albeit weakly. We observed maximum inhibition in the presence of octreotide 1O-9 M, the concentration which is achieved clinically following a single subcutaneous injection of octreotide (del Pozo et al., 1986) . The dose-response relationship in 3H-thymidine incorporation assay was similar to the 'bell-shaped' curve seen in cultured breast cancer cells (Setyono-Han et al., 1987) . This could have important implications for the clinical assessment of SS analogues, since the maximum tolerated dose may not necessarily have the greatest antitumour effect. None of our SSR negative cell lines were inhibited by octreotide, but neither was NCI-H69 which expresses high levels of SSR. However growth of this cell line was inhibited in vitro by two other octapeptide SS analogues, somatuline (BIM-23014C) and RC-160 (Taylor et al., 1988b, Dr A. Schally, personal communication) . Somatuline also inhibited the growth of NCI-H69 xenografts in vivo, especially when adminstered by perilesional infusion (Bogden et al., 1990) .
This clinical study was prompted by our in vitro data together with reports from other groups demonstrating experimental and clinical activity of SS analogues in NE tumours including SCLC. In using a brief course of octreotide in previously-untreated patients, we aimed to assess its effects first-line without delaying conventional treatment. None of six patients responded to octreotide but all subse- quently responded to combination chemotherapy. This is important since it has been suggested that front-line treatment with new agents may impair response to conventional therapy given second-line (Cullen et al., 1987 (Carney & Teeling, 1988; Nou et al., 1990) .
Serum IGF-I levels fell in most patients, probably reflecting suppression by octreotide of physiological (mainly hepatic) IGF-I secretion, as occurs in diabetics (Plewe et al., 1987) . In acromegalics treated with octreotide, serum IGF-I correlates well with levels of growth hormone and achievement of biochemical 'cure' (Lamberts et al., 1988) . This suggests that we had used an effective dose of octreotide, at least in endocrine terms. A recently reported study of eight patients with solid tumours (including cancers of the breast, pancreas, colon, kidney and ovary) showed similar reduction in circulating IGF-I levels on octreotide, although there were no data on clinical response, and suggested that suppression of serum IGF-I is in itself a promising approach to treatment (Pollack et al., 1989 to the point where their local tissue concentration would limit neoplastic growth. Any growth inhibition seems more likely to be mediated by a direct effect of SS analogues on the tumour cells themselves.
In summary, although octreotide has documented antitumour activity in other SSR positive NE tumours, we saw little correlation between SSR expression and growth inhibition in SCLC, either in vitro or clinically. This may be because the SSR detected on SCLC membranes do not mediate a growth inhibitory response, as has been demonstrated in meningiomas (Reubi et al., 1989 ). Alternatively we may have used a suboptimal dose or schedule of octreotide. If the dose-reponse curve is genuinely 'bell-shaped', as has been suggested in breast cancer (Setyono-Han et al., 1987) , the maximum tolerated dose may not necessarily have the greatest antiproliferative activity. Therefore it may be worth assessing other doses/schedules of octreotide administration, and other SS analogues reported to have pre-clinical activity in SCLC. In particular, analogues of the RC series including RC-160 have been shown to bind with higher affinity than octreotide to SSR on human tumour membranes (Srkalovic et al., 1990) . The RC analogues, but not octreotide have also been shown to stimulate dephosphorylation if the EGF receptor in pancreatic cancer cells (Liebow et al., 1989 ). This mechanism is not likely to be relevant in SCLC cells, which lack EGF receptors (Reubi et al., 1990) . Nevertheless, these studies suggest that some SS analgoues might be superior to others in terms of direct, receptor-mediated antitumour activity.
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